TTrialPathMatch Me to Trials
← Back to trials
RecruitingNon-Alcoholic Fatty Liver DiseaseNon-alcoholic Fatty LiverNon-alcoholic Steatohepatitis

European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)

Eligible age

Up to 18 yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The EU-PNAFLD (The European Paediatric NALFD Registry) will be a network composed of European centres involved in the care of children with NAFLD, and will include Hepatologists, Endocrinologists, and Scientists, supported by relevant international specialists. This collaboration will build on existing infrastructure (local databases and bio-repositories) and will align with the adult European NAFLD Registry ("EPoS", Elucidating Pathways of Steatohepatitis study) to allow long-term follow-up supported by translational studies. Through an international, well-characterised large-scale cohort, we hope to: facilitate multi-centre clinical trials; extend our understanding of the key disease mechanisms of NAFLD; and establish the natural history of paediatric NAFLD.

Sponsor: Cambridge University Hospitals NHS Foundation Trust

You may qualify if…

  • ✓ Diagnosis made under 18 years of age.
  • ✓ Diagnosis of NAFLD spectrum disease (simple steatosis (NAFL), steatosis with abnormal transaminases, NASH ± fibrosis or cirrhosis)
  • ✓ Diagnosis established by:
  • ✓ Radiological evidence of hepatic steatosis (e.g. increased hepatic echogenicity on ultrasound), with
  • ✓ Exclusion of secondary causes (negative serological liver screen for HBV/HCV, caeruloplasmin \>0.20g/L, no history of excess alcohol consumption, no evidence of iron overload, and no clinically significant alpha-1 antitrypsin (A1AT) phenotype (i.e. SZ, ZZ, SS), with or without
  • ✓ Histology (\>5% steatosis and histology consistent with paediatric NAFLD)

You may not qualify if…

  • ✕ Secondary fatty liver disease (e.g. glycogen storage diseases, Wilson disease, viral hepatitis, drug-related, autoimmune hepatitis, type 1 diabetes mellitus)
  • ✕ Post-transplant fatty liver
  • ✕ \>20g/day ethanol intake

Source: ClinicalTrials.gov · NCT04190849 · last updated 2022-03-04